@FiercePharma: Icahn is touting the Actavis-Forest deal as "another victory for activism." Release | Follow @FiercePharma
@EricPFierce: FDA picks 13 firms to participate in a pilot program that gives them expedited entry of 5 drugs to the U.S. Release | Follow @EricPFierce
@CarlyHFierce: From FiercePharmaMarketing: Eisai's revved-up Belviq marketing starting to pay off, analysts say. Story | Follow @CarlyHFierce
> Switzerland-based vaccine company Crucell, which is owned by Johnson & Johnson ($JNJ), has scaled back its layoff plans. Report
> India's Elder Pharma has appointed Deloitte to handle its restructuring. More
> Mapi Pharma has received a U.S. patent covering the process for the preparation of fingolimod, a.k.a. Novartis' ($NVS) multiple sclerosis pill Gilenya. Release
> An Oklahoma compounding pharmacy has agreed not to provide an execution drug for a Missouri inmate who has said it could cause severe and inhumane pain. News
And Finally... Doctors in California are training to identify the signs of ADHD in children. More (sub. req.)
@FierceMedDev: Our latest issue of FierceDiagnostics is ready for you. Highlights: news on a new depression biomarker and HIV tests. Report | Follow @FierceMedDev
@MarkHFierce: The rapidly escalating fortunes of a Chinese med device company created another billionaire there. Article | Follow @MarkHFierce
@MichaelGFierce: UCLA-developed contact lens uses a nanodiamond gel to deliver glaucoma drugs. More from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: ICYMI: Welsh government refuses to cover costs associated with faulty PIP breast implants. Item | Follow @EmilyWFierce
> Medtronic goes super tiny with its new wireless insertable cardiac monitoring device. Story
> Stryker's first M&A target of 2014: A German surgical equipment maker. More
> Medical device tax jobs toll: 33K and counting, says AdvaMed. Article
> J&J gets good news in vaginal mesh suit. News
Biotech News
@FierceBiotech: Cash-flush Versartis swings for an $80M IPO to advance its orphan drug. News | Follow @FierceBiotech
@JohnCFierce: AstraZeneca dispatches an advance science team to future HQ campus. Story | Follow @JohnCFierce
@DamianFierce: Lily moves on from a breast cancer setback as ramucirumab aces Phase III in lung cancer. More | Follow @DamianFierce
@EmilyMFierce: Acid-bath stem-cell study under investigation. Story via Nature | Follow @EmilyMFierce
> Chelsea wins FDA nod for once-spurned Northera, but success isn't guaranteed. More
> After a Phase II win, Novartis hints at an early app for its skin cancer pill. Article
Drug Delivery News
> UCLA-developed contact lens uses a nanodiamond gel to deliver glaucoma drugs. Article
> Targeted gold nanoshells radiate heat to improve cancer drug effect. Story
> 3M to develop inhaled airway inflammation treatments with Delaware's Invion. News
> Stem cell scaffold takes delivery issues out of tissue regeneration. Article
> 'Sticky' nanoparticles could help keep arteries open without a stent. Article
> With rejection, FDA says Durect's pain treatment Posidur needs further safety studies. Brief
Diagnostics News
> Cambridge U. researchers have discovered a biomarker for depression risk in boys. Article
> Sedia Biosciences wins NIH funding to develop an FDA-regulated HIV test. News
> Decision Diagnostics raised $12.7M for J&J glucose test strip patent countersuits. Story
> Ariosa's prenatal test gains crucial New York lab licensing certification. News
> Chembio teams with Malaysian outfit to bring its rapid HIV/syphilis tests into Asia. Story
> French operation raises nearly $56.4M to advance molecular imaging tools. Brief
Pharma Marketing News
> Novartis advertising probe intensifies with Tokyo office raid. News
> Simplify, simplify? FDA to study pared-down side effects in TV ads. Story
> Forest to discontinue old Namenda to 'force switch' patients to XR version. Article
> Sunshine Act data is now due, but some provisions remain murky. Story
> To win over patients, pharma needs to tell the truth, and nothing but, expert says. Analysis
> Chelsea scored FDA approval for Northera, but the launch is no sure bet. Item